Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

MHRA joins Instagram as part of Yellow Card drive

UK medicines regulator follows in the footsteps of NICE in using the channel

MHRA Instagram

The MHRA has increased its use of social media for its latest campaign to encourage the public to report any suspected side effects from taking over-the-counter medicines.

In joining Instagram, where it is @mhragovuk, the MHRA follows in the footsteps of England and Wales’ HTA body NICE (@nicecomms), which launched on the channel at the beginning of this month.

NICE has focused on AMR and diabetes to date, while the UK medicines regulator has so far been using Instgram to encourage the use of its Yellow Card scheme.

All regulatory reporting systems suffering from under-reporting and the MHRA hopes that its latest campaign will “both raise awareness and help strengthen the system”.

Mick Foy, group manager for MHRA’s Vigilance and Risk Management of Medicines division, said: “our campaign will help the public, patients and healthcare professionals report potential side effects and have confidence that their reports are making a difference.”

The MHRA’s social media campaign, of which its new Instagram account is just one element, is part of Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE), a joint action project funded by the European Union.

22nd November 2017

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics